Results of repeat biopsies under electronically tracked, MRI/TRUS fusion guidance

Dr. Leonard Marks and colleagues at the University of California, Los Angeles were among the earliest groups to start to use and publish data on MRI/TRUS fusion biopsies of the prostate. They have now reported some early data on repeat biopsies using such methodology in men on active surveillance. … READ MORE …

Do you have Stage IV or metastatic prostate cancer?

We understand that Health Monitor magazine is looking for a few men with Stage IV or metastatic prostate cancer (and possibly their spouses/partners) who are willing to be professionally interviewed. The magazine has a tight timeline. … READ MORE …

The “right” to investigational drug therapy “to save your life”

This November, voters in Arizona will get to determine whether, in their opinions, terminally ill patients should be entitled to have unfettered access to drugs that are in early-stage development but haven’t been approved by the U.S. Food and Drug Administration (FDA). … READ MORE …

Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

When is active surveillance not really active surveillance?

A story that got wide coverage yesterday (in the cancer-specific media, at least) said that “research published online in the Journal of Clinical Oncology suggests that ‘active surveillance for clinical stage I (CSI) testicular cancer leads to excellent outcomes’.” … READ MORE …

The PROSPECT trial in men with mCRPC — an update

One of the more intriguing Phase III clinical trials going on at this time is the PROSPECT  trial, which is a randomized, double-blind, multi-center trial of PROSTVAC with or without GM-CSF in men with asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer (mCRPC). … READ MORE …

Short-term outcomes after prostate cancer diagnosis and treatment in France

An article available in full on the Medscape web site provides an overview of short-term outcomes of > 43,000 men diagnosed with prostate cancer in France in 2009 and followed for 2 years based on data in the French national health insurance information system (SNIIRAM). You do need to register with Medscape to be able to read the article (but registration is free). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers